In allergies, an unbalanced immune response towards a T helper (Th) 2 profile with high levels of Immunoglobulin (Ig) E is produced. We have demonstrated that the pre-administration of Enterococcus faecalis CECT7121 prevents the development of allergy in ovalbumin-immunized mice. In this work, we evaluated whether this bacterium can also revert an established allergic status. Mice were immunized with ovalbumin (OVA) and after that, were inoculated with an E. faecalis CECT7121 suspension. In immunized animals, serum specific immune response, proliferative activity of memory splenocytes, and levels of Th2 cytokines were assessed. The in vivo active cutaneous anaphylaxis test was also performed. The treatment with E. faecalis CECT7121 only increased anti-OVA IgG2a levels. No differences were observed in other specific immunological parameters. Probiotic-treatment did not prove to have any desensitizing effect on mice. These results, together with those recently published, can be concluded that this bacterium would not be appropriate for the treatment of allergic symptoms.
Introduction
In most individuals suffering from allergic diseases, an imbalance of the immune response towards a Th2 cytokine profile is observed. This Th2 scenario induces the secretion of high levels of IgE, together with the recruitment of effect or cells to the site where the allergic inflammatory response is taking place [1] [2] [3] [4] [5] . On the other hand, it is known that in healthy individuals, a Th1 response is generated against allergens [6] . According to the hygiene hypothesis [5] [7] [8] [9] , the exposition to microorganisms during the early stages of life could revert this Th2-skewed response, and in turn, it could induce the development of a Th1 phenotype and stimulate the activity of Treg cells. This observation has led to the experimental use of microorganisms to prevent or inhibit allergic diseases, being the probiotics, the most promising tool for this purpose [10] . There are prominent studies about probiotic pre-treatment which are successfully employed in allergies in different models. One of the beneficial effects that have been reported is a reduction in the production of serum-specific IgE in mice [11] [12] [13] .
Probiotic bacteria can induce immune regulation or immune tolerance in allergic diseases as it had been demonstrated in a β-lactoglobulin-induced intestinal anaphylaxis in a murine model of food allergy where the oral administration of Clostridium butyricum CGMCC0313-1 ameliorated intestinal anaphylaxis symptoms and shifted the immune balance towards Th1 and Treg, with significantly increased Foxp3/Rorγt and Foxp3/Gata ratios and a significantly decreased Ga-ta3/Tbet ratio [14] . Furthermore, there are other studies that show that the probiotic administration induces an improvement on allergic symptoms. Yang et al. have observed that the treatment for two weeks with Bifidobacterium infantis during OVA sensitization attenuated the serum specific IgE and IgG1 secretion as well as reduced Th2-type cytokines in spleen cell supernatants and, after challenge with OVA, probiotic-treated mice showed lower allergic reaction measured as diarrhea than sensitized-mice [15] .
Enterococcus faecalis strains are frequently isolated from food products, and certain strains have been used as cheese starter and food products in the market worldwide [16] . Moreover, they are also employed as probiotics in many applications for human and animals [17] . We have previously worked with a nonpathogenic strain, Enterococcus faecalis CECT7121, isolated from natural corn silage [18] . We have evidenced that this strain implants and remains in the intestinal mucosa of BALB/c mice, stimulating the immune system [19] [20] . We have also demonstrated the adjuvant effect of E. faecalis CECT7121 and its broad pro-Th1 immunomodulatory activity, achieving beneficial effects on different experimental models [19] [21] [22] [23] .
The immunomodulatory effect of E. faecalis CECT7121 has been demonstrated in an allergy model induced by the subcutaneous (s.c.) administration of Ovalbumin (OVA), where this strain was able to diminish the secretion of specific IgE and to induce an increase in the levels of specific IgG2a. This probiotic also decreased the proliferation of splenocytes and the secretion of Th2 cytokines [23] . In the latter model, we have demonstrated that the previous implantation of E. faecalis CECT7121 in the intestinal mucosa prevents the development of the allergic status. In order to perform a more insightful assessment of the immunomodulatory capacity of this probiotic, in this work, we evaluated whether this probiotic can also revert an established allergic status. Considering that probiotic immunomodulatory capacity is broadly assessed as pre-treatment in allergy models, but there is little information about probiotic post-treatment in an established allergy model, in this work we evaluated whether E. faecalis CECT7121 can also revert an established allergic status. For that reason, OVA-sensitized mice were treated with the probiotic by the intragastric (i.g.) route, evaluating parameters of the Th-2 biased immune response induced by the allergen.
Materials and Methods

Mice
Conventional female BALB/c mice were provided by the School of Veterinary weeks old at the beginning of the experiment.
All animal experiments were approved by the Instituto de Estudios de la Inmunidad Humoral "Prof. Dr. Ricardo A. Margni" (IDEHU, CONICET-UBA).
Maximum efforts were undertaken to minimize animal suffering in all procedures.
Immunization Protocol with OVA and i.g. Administration of Ent. faecalis CECT7121
Mice were divided in two experimental groups: E. faecalis CECT7121/ OVA (n = 6), S/OVA (saline) (n = 6). OVA immunization [10 μg OVA and 1 mg Al(OH) 3 ] was performed on days 0, 7 and 21 by s.c. injection (0.2 ml) on the back of each mouse ( Figure 1 ). An E. faecalis CECT7121 suspension (3 × 10 8 CFU/ml, prepared as previously described [23] was administrated by the i.g. route (0.2 ml/mice/day) with a gavage needle on three doses: days 1, 2 and 3; days 13, 14
and 15 and on days 28, 29 and 30. On day 34, serum samples were obtained and mice were euthanized by CO 2 or cervical dislocation and spleens removed.
Another group of mice was subjected to the Active Cutaneous Anaphylaxis Test (ACA). Control non-immunized animals were treated with saline instead OVA or E. faecalis CECT7121 (n = 3 each).
Evaluation of Cell Responses
Individual spleen cell suspensions of each mice were prepared in RPMI 1640 medium (Gibco) containing fetal calf serum (Natocor), penicillin (Gibco), streptomycin (Gibco), amphotericin B (Gibco), L -glutamine (Gibco) and pyruvate (J.T. Baker) as previously described [23] . One hundred microlitres of spleen cell suspension (4 × 10 6 cells/ml) were cultured with 100 μl of ulture medium 
Levels of Cytokines and Allergen-Specific Antibodies
Active Cutaneous Anaphylaxis
Active Animals were observed after 30 min.
Statistical Analysis
Two separate immunization schedules were carried out. All values were pre- 
Results and Discussion
The aim of this work was to study the effect E. faecalis CECT7121 during the effector phase of the allergic response. We evaluated whether this strain could also revert Th2 parameters of the allergic response in an experimental allergy model induced by s.c. OVA administration. The parameters assessed ex vivo were secretion of specific IgE, IgG1, IgG2a antibodies and the Th2 cytokines in splenocyte culture supernatants. In addition, an in vivo of the ACA test was performed.
The development of the allergic response comprises two phases. The first one, or sensitization phase, is that CD4 + T cells become activated and differentiated into Th2 IL-4, IL-5 and IL-13-secreting cells. These cytokines would induce the secretion of IgE and IgG1 by B cells. Both basophils and mast cells have on the cell surface of the high affinity IgE receptor (FcεI), allowing this immunoglobulin to bind to the cell membrane. During a second exposure to the allergen, those IgE molecules bound to the FcεI induce the receptor cross-linking leading to cell activation and the subsequent degranulation and the release of histamine, which is one of the soluble mediators responsible for the appearance of clinical symptoms of allergy. Probiotics as lactic acid bacteria have immunomodulating effects, as a reduction in the production of antigen specific serum IgE production, which is affected by IL-4 and IL-5 produced by Th2 cells [11] months to their infants was effective in prevention of early atopic disease in children [25] .
The treatment of allergy employing probiotic microorganisms can be employed to modulate either the sensitization or the effector phase of the response. The immunomodulatory activity of probiotics and the period of time over which they have positive effects are highly dependent on the strain under study, but also with the dose, the timing of supplementation and the method of administration [26] [27] [28] . Previously, our group has demonstrated that the i.g. administration of Enterococcus faecalis CECT7121, prior to the sensitization induced by the administration of OVA, can prevent the establishment of the allergic response [23] .
In the present work, on day 34 after the first immunization with OVA and E. faecalis CECT7121 treatment protocols, Th1 and Th2 parameters of the immune response were assessed. Levels of specific anti-OVA IgE and IgG1 (Th2-immunoglobulins) and IgG2a (Th1-immunoglobulin) were determined.
No detectable specific immunoglobulins were found in non-immunized animals (treated or not with the probiotic; data not shown). Upon analyzing the Th2 immunoglobulin IgE, it was found that the levels of this specific anti-OVA isotype were not affected by the treatment of animals with the probiotic (Table 1) .
No statistical differences were found in the titres of specific IgG1 between immunized control group and those treated with the probiotic (Table 1) . Contrarily, the levels of specific IgG2a were found to be higher in the group of animals immunized with OVA and treated with E. faecalis CECT7121 ( Table 1 ). The IgG1/IgG2a ratios, therefore, were found to be significantly different between both groups of animals. The decrease in the anti-OVA IgG1/IgG2a ratios observed in the group of animals treated with the bacterium accounted for a rise in the levels of specific IgG2a. The latter finding is in line with the pro-Th1 activity already reported for E. faecalis CECT7121 [19] [21] [22] .
After The proliferation rates of splenocytes obtained from both E. faecalis CECT7121-treated and untreated control animals did not differ from each other after the in vitro stimulation with OVA ( Figure 2 ). Moreover, after stimulation with OVA, these splenocytes were able to secrete the Th2-related cytokines IL-5, IL-13 and the regulatory IL-10; however, no differences were found between animals immunized with OVA and those immunized and treated with E. faecalis CECT7121 (Figure 3 ) which indicates that this bacterium was not able to decrease the levels of the cytokines evaluated ( Figure 3 ). These results are in agreement with the titres of specific IgE found in allergic animals, since it is known that IL-4, IL-5 and IL-13 are the cytokines involved in IgE synthesis regulation [2] [29] [30] .
Even though the immunological ex vivo determinations indicated that E. faecalis CECT7121 was incapable of reverting the allergic status, the in vivo ACA test was performed, since it has been demonstrated that this test can account for amelioration of the allergic symptoms, as is the case of the treatment with Lactococcus lactis NCC2287, even when a decrease in the levels of specific antibodies is not observed [31] . In the ACA test carried out in our model, those animals belonging to the E. faecalis CECT7121/OVA group displayed the same degree of dye extravasation as control S/OVA animals (Figure 4 ), evidencing vasodilatation and a vascular permeability increase caused by mast cells degranulation.
Taking into account the results obtained herein, together with those published demonstrating the preventive effect of E. faecalis CECT7121 on the development of allergy [23] , it can be concluded that this bacterium as it was administered could decrease the anti-OVA IgG1/IgG2a ratios observed in the group of animals treated with the bacterium due to a rise in the levels of specific IgG2a, but it could not reduce IgE levels nor show differences in the ACA test, so it would not be appropriate for the treatment of allergic symptoms in the OVA allergy induced model. These results reinforce the hypothesis that each probiotic strain can have a differential effect on both phases of the allergic response.
